4.7 C
New York
Wednesday, December 6, 2023

The Question Is Whether To Buy Or Not To Buy Bluebird bio Inc (NASDAQ: BLUE)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Bluebird bio Inc (BLUE) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.20, or 6.06%, to $3.50. The Bluebird bio Inc has recorded 28,346 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

Stocks Info

Bluebird bio Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $3.30 and fluctuated between $3.5799 as its day high and $3.2700 as its day low. The current market capitalization of Bluebird bio Inc is $352.93M. A total of 3.51 million shares were traded on the day, compared to an average of 3.60M shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, BLUE has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 17,851 shares. Over the last 12 months, there were 12 BUYs and 9 SELLs from insiders. Insiders purchased 347,003 shares during that period but sold 34,839.

In the most recent transaction, Obenshain Andrew sold 807 shares of BLUE for 3.17 per share on Nov 03. After the transaction, the President and CEO now owns 291,134 company shares. In a previous transaction on Nov 02, Colvin Richard A sold 2,343 shares at 2.98 per share. BLUE shares that Chief Medical Officer owns now total 125,735.

Among the insiders who sold shares, Klima Thomas J disposed of 922 shares on Sep 05 at a per-share price of $3.79. This resulted in the insider holding 132,127 shares of BLUE after the transaction. In another insider transaction, Obenshain Andrew sold 16,929 shares at $3.54 per share on Aug 10. Company shares held by the President and CEO now total 291,941.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for BLUE in the last 3 months, the mean price target is $7.10 with high estimates of $11.00 and low estimates of $3.00. In terms of 52-week highs and lows, BLUE has a high of $8.58 and a low of $2.52.

As of this writing, BLUE has an earnings estimate of -$0.67 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of -$0.51 per share and a lower estimate of -$0.83. The company reported an EPS of $0.21 in the last quarter, which was 156.80% higher than expectations of -$0.37.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BLUE’s latest balance sheet shows that the firm has $396.62M in Cash & Short Term Investments as of fiscal 2021. There were $89.58M in debt and $152.99M in liabilities at the time. Its Book Value Per Share was $2.71, while its Total Shareholder’s Equity was $374.28M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BLUE is Buy with a score of 3.67.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles